C33H57N11O9 · 751.9 g/mol · PubChem CID 11765600 ↗
Selank
also known as Selanc, Selankum, TP-7
Synthetic 7-amino-acid peptide developed at the Russian Academy of Medical Sciences from the immunomodulator tuftsin. Reported in Russian clinical studies to produce anxiolytic effects without sedation or dependence. Acts via modulation of monoamine neurotransmission and the immune-CNS axis. Licensed in Russia + Ukraine; not approved elsewhere.
- Class
- Heptapeptide bioregulator
- Evidence level
- Human mechanistic evidence
- Regulatory status
- Not FDA-approved (US) — research use only
At a glance
Intranasal · 2–3×/day during stress / cognitive demand
Primary target — Monoamine system (serotonin / GABA modulation) + immunomodulation via tuftsin domain [zaderej-2014].
Pathway — Tuftsin-derived immune signaling + CNS monoamine modulation → reduced anxiety + improved mood / cognition [medvedev-2007].
Downstream effect — Anxiolytic + cognitive enhancement; immunomodulation via increased IL-6 + IFN-γ [medvedev-2007][zaderej-2014].
Origin — Synthetic 7-AA peptide derived from human tuftsin (immune-system tetrapeptide) [zaderej-2014].
Feedback intact — No GABA-receptor binding; no dependence reported [medvedev-2007].
| Parameter | Value |
|---|---|
| Standard dose | 150–300 mcg / dose intranasal [zaderej-2014] |
| Frequency | 2–3× per day during stress |
| Lower / starter dose | 75 mcg / dose |
| Evidence basis | Human-mechanistic + Russian clinical trials [medvedev-2007] |
| Duration | 10–14 day cycles, repeated as needed |
| Reconstitution | Pre-formulated nasal spray (commercial); research vial: bacteriostatic water |
| Timing | Morning + early afternoon preferred |
| Half-life | Short (minutes plasma); CNS effect lasts ~3 hr |
Reconstitution
A pure mass-to-volume utility. Enter what you have in the vial; the atlas computes the volume per dose. No prescription information.
Lab verification
Third-party lab reports tied to batch codes, re-verifiable at the issuing lab. A fact and where to re-check it — never a verdict.
Evidence base: Russian-language clinical literature, primarily from the St. Petersburg Institute of Bioregulation and Gerontology (Khavinson school), 1985 onward. Not extensively peer-reviewed in Western journals.
- — Pregnancy / breastfeeding
- — Hypersensitivity to peptide
- — Active autoimmune disease (theoretical via immunomodulation)
- 01Form
Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.
- 02Administration
Intranasal — 1–3 sprays per nostril per dose. Tilt head slightly back.
- 03Timing
Morning + early afternoon for cognitive demand; PRN for acute anxiety.
- 04Storage
Refrigerate after reconstitution; ≤30 days. Light-protected.
- 05Caveat
Avoid co-administration with strong sedatives or other anxiolytics initially.
Frequently asked
How does Selank work?
Selank acts on Monoamine system (serotonin / GABA modulation) + immunomodulation via tuftsin domain, signalling via Tuftsin-derived immune signaling + CNS monoamine modulation → reduced anxiety + improved mood / cognition. [zaderej-2014][medvedev-2007]
Is Selank FDA-approved?
Selank is not FDA-approved in the United States and is handled as a research compound (research use only). Regulatory status may differ in other jurisdictions.
Sources
of 40 rendered claims carry a resolvable citation.
- [medvedev-2007]Medvedev 2007 — Pharmacology of Selank — anti-anxiety + cognitive effects
Eksp Klin Farmakol, 2007
Not PubMed-indexed. Russian-language Selank pharmacology paper. - [zaderej-2014]Zaderej 2014 — Selank: anxiolytic effects + immunomodulation
Bull Exp Biol Med, 2014
Selank Russian anxiolytic peptide review.